Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

By sjmartinez • March 30, 2025

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K, Hamidi A, Chesney J. Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. Oncologist. 2025 Mar 10;30(3):oyae203. doi: 10.1093/oncolo/oyae203. PMID: 40156118.

Tags: Hematology/Oncology, Hepatocellular carcinoma, liver metastasis, pembrolizumab, Publications, Solid tumor, talimogene laherparepvec

Related Posts

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim[...]

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma

O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ,[...]